Descripción de la empresa
Acurx Pharmaceuticals, Inc. operates within the healthcare sector, specifically focusing on the biotechnology industry, where it develops antibiotics to address bacterial infections in the United States market. The company's primary strategic focus is on its lead antibiotic candidate, ibezapolstat, which utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme and is currently progressing through Phase 2b clinical trials. In terms of scale, the entity maintains a market capitalization of $8.76M and employs a workforce of 4 individuals, reflecting a highly concentrated operational structure typical of early-stage clinical development firms. The combination of a market cap under $10 million and the absence of reported annual revenue figures indicates that the company is in a pre-commercialization phase, where value is derived primarily from intellectual property and clinical data rather than sales traction. This financial positioning suggests that the enterprise is allocating resources toward research and development activities rather than revenue generation, a characteristic common for biotechnology companies advancing candidates through pivotal clinical stages.
Salud financiera
The financial statements reveal a net income of $-7,966,538 for the trailing twelve months, while both revenue and EBITDA are listed as not available, indicating that the company has not yet generated positive sales or operating earnings. The significant gap between the reported net income loss and the zero revenue implies a cost structure driven almost entirely by research, development, and operational overhead expenses incurred during the clinical trial process. Free cash flow stands at $-4,291,853, which signifies a substantial cash outflow required to fund ongoing clinical operations and maintain the company's research pipeline without external revenue support. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a standard outcome for entities that have not yet achieved commercial product sales or have not recognized revenue against their high burn rates. The company holds $7.56M in cash reserves with no debt on record, creating a scenario where total cash significantly exceeds total liabilities. The debt-to-equity ratio is not applicable due to the absence of debt, suggesting a conservative balance sheet approach that prioritizes liquidity preservation over leverage. Liquidity is further evidenced by a current ratio of 3.18, indicating that the company possesses sufficient short-term assets to cover its short-term obligations more than three times over. Return on Equity is reported at -270.8% and Return on Assets at -87.6%, metrics that reveal that management's effectiveness in generating profits is currently negative as the company invests capital into clinical progress rather than returning value through earnings.
Evaluación de valoración
Valuation multiples for the company are distorted by the lack of earnings, with the trailing P/E ratio listed as not available and the forward P/E standing at -1.40. The negative forward P/E ratio implies that the market is pricing in future earnings potential that has not yet been realized, rather than basing value on current profitability. The price-to-book ratio is 1.37, indicating that the market values the company at 37% above its book value, which may reflect expectations of the clinical asset's potential despite current losses. Alternative valuation metrics such as price-to-sales and EV/EBITDA are not available, suggesting that traditional valuation models reliant on revenue or earnings generation cannot currently be applied to this biotechnology asset. The stock price has exhibited extreme volatility, trading between a 52-week high of $21.00 and a 52-week low of $1.33. Without a specific current price to calculate the exact percentage from the provided data, the range demonstrates a wide trading band typical of micro-cap biotechnology stocks with high risk profiles. The beta value of -1.92 indicates that the stock's price movements are inversely correlated to the broader market, moving in the opposite direction with high intensity relative to market benchmarks.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both not available, as the company has not yet generated positive revenue streams to calculate growth rates. The absence of growth data suggests that the company is still in the foundational stages of product development where historical sales data does not exist to compare against future projections. As a non-dividend payer, the company does not distribute a dividend yield or a payout ratio, as these metrics are not applicable to an entity focused on clinical-stage research. Consequently, the company retains all available cash reserves to reinvest into the development of ibezapolstat rather than distributing income to shareholders. The overall growth and income profile is characterized by a complete reliance on capital markets or cash reserves to fund operations, with no current income generation or dividend distribution mechanisms in place. This profile is consistent with clinical-stage biopharmaceutical companies that prioritize advancing their pipeline through regulatory milestones before considering commercialization and shareholder returns.